Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 12/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 13/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725500 | 0.92 | XIAP (0.43) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL1635019 | 0.92 | XIAP (0.43) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL1635017 | 0.92 | XIAP (0.43) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL3811996 | 0.90 | XIAP (0.46) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL3815022 | 0.90 | XIAP (0.47) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL3819865 | 0.89 | XIAP (0.45) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL4902289 | 0.87 | XIAP (0.44) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL12467055 | 0.86 | XIAP (0.42) | XIAPBIRC3CASP9BIRC2MEN1 | |
| SCHEMBL1635042 | 0.86 | XIAP (0.44) | XIAPBIRC3CASP9BIRC2TSHR | |
| SCHEMBL12467460 | 0.86 | XIAP (0.42) | XIAPBIRC3CASP9BIRC2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183955-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7932255-B2 | Controlling cell proliferation | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932255-B2 | Controlling cell proliferation | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-1874748-B1 | 2 -AMINOCARBONYL SUBSTITUTED PIPERAZINE OR DIAZA-CYCLIC COMPOUNDS AS APOPTOSIS PROTEIN INHIBITOR (IAP) MODULATORS | NOVARTIS AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | ECKL ROBERT | 2008-08-28 | — | — | US | disclosed |
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | ECKL ROBERT | 2008-08-28 | — | — | US | disclosed |
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | ECKL ROBERT | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | API5, BCL2, BIRC5 | XIAP 8/4885BIRC3 6/4885CASP9 49/4885 |
| US-20110183955-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | API5, BCL2, BIRC5 | XIAP 8/4885BIRC3 6/4885CASP9 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.